Literature DB >> 1705242

Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin.

B Boyd1, S Richardson, J Gariepy.   

Abstract

The B subunit of Shiga toxin and Shiga-like toxin (SLT-1) and its fragments are potentially immunogenic and may generate protective humoral responses against the action of these toxins. We have analyzed the antibody response of rabbits immunized with pure B subunit of SLT-1 or synthetic fragments of the subunit. The immune response to the native B subunit was found to be largely directed at conformational epitopes. More importantly, rabbits immunized with the B subunit were protected from a lethal challenge with SLT-1, indicating that the B subunit represents an excellent vaccine candidate to counter the effects of Shiga toxin and SLT-1 in humans. Polyclonal antibodies against a synthetic peptide corresponding to residues 28 to 40 of the B subunit neutralized the cytotoxicity of SLT-1 towards Vero cells. This region is thus exposed in the native state of the B subunit. The sequence specificity of other antipeptide antisera also provides clues to the state of folding and assembly of the B subunit. Antisera to synthetic peptides representing the N- and C-terminal regions of the SLT-1 B subunit did not cross-react with native B subunit but strongly recognized denatured forms of the protein. Finally, the monoclonal antibody 13C4 was shown to bind to a discontinuous epitope expressed only on the native form of the protein. These immunological reagents can be used to probe the conformational state of the B subunit and the holotoxin as it relates to their functional properties.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705242      PMCID: PMC258323          DOI: 10.1128/iai.59.3.750-757.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  The preparation and enzymatic hydrolysis of reduced and S-carboxymethylated proteins.

Authors:  A M CRESTFIELD; S MOORE; W H STEIN
Journal:  J Biol Chem       Date:  1963-02       Impact factor: 5.157

2.  Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1.

Authors:  A Fontaine; J Arondel; P J Sansonetti
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

3.  Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity.

Authors:  I Harari; A Donohue-Rolfe; G Keusch; R Arnon
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

4.  Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2.

Authors:  T Waddell; S Head; M Petric; A Cohen; C Lingwood
Journal:  Biochem Biophys Res Commun       Date:  1988-04-29       Impact factor: 3.575

5.  Direct cytotoxic action of Shiga toxin on human vascular endothelial cells.

Authors:  T G Obrig; P J Del Vecchio; J E Brown; T P Moran; B M Rowland; T K Judge; S W Rothman
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

6.  Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1.

Authors:  A A Lindberg; J E Brown; N Strömberg; M Westling-Ryd; J E Schultz; K A Karlsson
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

7.  Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.

Authors:  C A Lingwood; H Law; S Richardson; M Petric; J L Brunton; S De Grandis; M Karmali
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

8.  Verotoxin receptor glycolipid in human renal tissue.

Authors:  B Boyd; C Lingwood
Journal:  Nephron       Date:  1989       Impact factor: 2.847

9.  Cytotoxicity of Shiga toxin for primary cultures of human colonic and ileal epithelial cells.

Authors:  M P Moyer; P S Dixon; S W Rothman; J E Brown
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

10.  Strain-specific and common epitopes of gonococcal pili.

Authors:  J B Rothbard; R Fernandez; G K Schoolnik
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more
  16 in total

1.  The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide.

Authors:  Michael J Smith; Humberto M Carvalho; Angela R Melton-Celsa; Alison D O'Brien
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

2.  Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30.

Authors:  D J Bast; J Sandhu; N Hozumi; B Barber; J Brunton
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity.

Authors:  H Nakao; N Kiyokawa; J Fujimoto; S Yamasaki; T Takeda
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia.

Authors:  Paola Marcato; Thomas P Griener; George L Mulvey; Glen D Armstrong
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls.

Authors:  M Bitzan; M Klemt; R Steffens; D E Müller-Wiefel
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

6.  Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains.

Authors:  J R Butterton; E T Ryan; D W Acheson; S B Calderwood
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

7.  Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit.

Authors:  Tao Wu; Christen Grassel; Myron M Levine; Eileen M Barry
Journal:  Infect Immun       Date:  2011-10-03       Impact factor: 3.441

8.  Synthesis of an Aminooxy Derivative of the Trisaccharide Globotriose Gb3.

Authors:  Samir Ghosh; Peter R Andreana
Journal:  J Carbohydr Chem       Date:  2014-09-01       Impact factor: 1.667

9.  Protection of mice against Shiga toxin 2 (Stx2)-associated damage by maternal immunization with a Brucella lumazine synthase-Stx2 B subunit chimera.

Authors:  María Pilar Mejias; Gabriel Cabrera; Romina Jimena Fernández-Brando; Ariela Baschkier; Giselle Ghersi; Maria Jimena Abrey-Recalde; Elizabeth Miliwebsky; Roberto Meiss; Fernando Goldbaum; Vanesa Zylberman; Marta Rivas; Marina Sandra Palermo
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

10.  Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling.

Authors:  Beth Binnington; Long Nguyen; Mustafa Kamani; Delowar Hossain; David L Marks; Monique Budani; Clifford A Lingwood
Journal:  Glycobiology       Date:  2015-09-24       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.